Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Trading Statement

20 Jan 2010 07:00

RNS Number : 8147F
PuriCore Plc
20 January 2010
Β 

ο»Ώ

PuriCore Pre-CloseΒ Trading UpdateΒ for Year Ended 31 December 2009

Increased Revenues of 28%Β and Significant Business Development

MALVERN, PENNSYLVANIA, AND STAFFORD, UK,Β 20 JanuaryΒ 2010Β -Β PuriCoreΒ (LSE: PURI), theΒ water-based clean technologyΒ company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, announcesΒ itsΒ pre-closeΒ trading update for the year ended 31 December 2009.Β Audited results for this period are expected to be announced in late April 2009.

Q4 and Full-YearΒ Financial ResultsΒ (unaudited)

Q4 sales of $10.4Β million (2008: $5.9Β million), an increase ofΒ 75% (72% increase at constant currency)
US Food Safety revenue increasedΒ 42% to $4.6Β millionΒ 

UK EndoscopyΒ revenue increased 121% to $5.7 million (113%Β increaseΒ at constant currency)Β 

2009 sales of $40.0 million (2008: $33.8Β million), an increase of 19% (28% increase at constant currency)
North AmericanΒ Food Safety revenueΒ increased 19%Β to $23.1 millionΒ 

UK EndoscopyΒ revenue, including Labcaire revenue as at August 2009,Β increased 19%Β to $16.4 million (41% increase at constant currency)

EarningsΒ estimatedΒ to be belowΒ Director'sΒ expectations, but not significantly so,Β due toΒ delays of expected Endoscopy sales into the next periodΒ and higher than anticipated field costsΒ 

Cash of $5.3 million at period end
Debt reduced approximately $4.6 millionΒ (including $2.2 million related to Labcaire Systems)
Receivables and inventory increased a total of approximately $1.6 million

2009Β Operational Highlights

Endoscopy
Completed acquisition of Labcaire Systems, a major UK endoscopy provider

Launched Endoscopy on Demand and a new pass-through reprocessor

Food Safety
Completed installation in all US and Canadian stores of Safeway, a top-five US supermarket retailer
Awarded contract and completed installation for the remaining Supervalu stores, another top-five US supermarket retailer
Expanded customer base from 30 to 53 brands including another top-10 US supermarket and leading regional chains
Wound Care
Achieved positive results for Vashe Wound Therapy in a clinical burn study

Received a new FDA 510(k) with expanded shelf-life claims

Completed Successful FundraisingsΒ 
Β£2 million equity (gross) raised in a PlacingΒ to fund the acquisition of Labcaire SystemsΒ 
$2.7Β million raised throughΒ theΒ issuance of debtΒ 

Greg Bosch, Chief Executive of PuriCore, said:

"2009 was a strong year forΒ PuriCoreΒ with record revenues in both core businesses despite the challenging economic climate. In our Food Safety business, we achieved record shipments with continued traction with the top national and regional retailers. Our Endoscopy business, including the acquisition of Labcaire, grew revenues more than 40% for the second year in a row and is now positioned as the top UK endoscopy disinfectant equipment and service provider. The integration of the Labcaire business is on schedule and proceeding smoothly. Looking ahead, we remain keenly focused on continuing to increase revenues, improve gross margins, and leverage our operating expenses in our core businesses whilst developing a third business franchise for our water-based clean technology."

Company Results

PuriCore achieved record results for the year with 28% top-line growth (at constant currency) and total revenues of $40.0 million. The Company expects to report a significant improvement in operating loss compared with prior year but a negative variance to Directors' expectations due toΒ delays of expected Endoscopy sales into the next period and higher than anticipated fieldΒ costs during the year, which the Company anticipates to be reduced going forward.Β The Company continued to reduce operating expenses throughout the year on its legacy business excluding the impact of Labcaire.Β PuriCore successfully completed fundraisings during the year including an equity Placing that raisedΒ Β£2 million (gross) to fund the acquisition of Labcaire Systems and the issuances of debt raising $2.7 million to fund leases in the Food Safety business.Β The Company's cash and cash equivalents at year end totalled $5.3 million.Β 

Food Safety

PuriCore's Food Safety business in North America again achieved outstanding growth, driven in large part by the completion of installations of Sterilox Systems by the major nationals (now two of the top-five US retailers) in all of their stores. During the year,Β PuriCore completed the system-wide installation of Sterilox Food Safety Systems in all US and Canadian stores of Safeway, a top-five US supermarket retailer.Β The CompanyΒ alsoΒ won a contract and completed installationΒ inΒ the remaining Supervalu stores, another top-five US supermarket retailer.Β At year end, the CompanyΒ had increased its customer footprint from 30 to 53 retail brands including another top-10 US retailer and several leading regional chains.Β The Company installed approximately 1,250Β new SteriloxΒ Food Safety Systems across the US and Canada in 2009,Β bringing its total installed base to approximately 3,650Β SystemsΒ in the 53 retail brands. These brandsΒ represent approximately 20% of PuriCore's current targeted market of 29,000 North American stores, of which the Company has already installed 12%.Β As at 31 December 2009,Β PuriCore hadΒ sales opportunitiesΒ with other customers in negotiations, trials, or discussionsΒ representing an additionalΒ 40% of the market.Β The Company further estimates it could place aΒ second Sterilox system in approximately half of the North American stores for additional applications.Β 

Endoscopy

With the acquisition of Labcaire Systems in August, PuriCore estimates its Endoscopy business is now the largest provider of endoscope disinfection equipment and services to UK NHS hospitals, private hospitals, and primary care networks. PuriCore Endoscopy had significant growth of 41% in 2009 on a constant-currency basis (including Labcaire Systems revenues as at August 2009) despite a clearly challenging economic environment. This growth performance was a function of increased unit placements as well as increased recurring revenue streams from lease contracts, service agreements, and related consumable products. During the year, PuriCore launched a new managed service, Endoscopy on Demand, and pass-through automated endoscopy reprocessor to meet market demand. At year end, PuriCore Endoscopy had placed reprocessing systems in approximately 350 NHS hospitals with endoscopy departments.Β 

New Markets

In 2009,Β PuriCore transitioned exclusively from a clinical development programme toΒ Β commercialisation of the VasheΒ Wound Therapy platform. To dateΒ there have been more thanΒ 160,000 successful Vashe treatments, with totalΒ 2009 sales of $0.5Β millionΒ (inclusive of Dental revenues).Β The Company received a new FDA 510(k) clearance for Vashe Wound Therapy, which extends the shelf lifeΒ and enables wound care clinics greater flexibility in use of the therapy. In late 2009, a clinical study presented highlighted Vashe Wound Therapy as an effective and economical therapy for burn wounds.

2010Β Outlook

In 2010, the companyΒ anticipatesΒ cash flowΒ profitability inΒ PuriCore's Endoscopy business in the UK and continued significant progress in the Food Safety business in both the US and Canada.Β Throughout the year,Β PuriCoreΒ will continue to focus on growth in its two core businesses: North American Food Safety and UK Endoscopy, and further establish its Wound Care market presence.Β Consistent with past practice, the CompanyΒ will seek debt financing for leased systems and continue to review additionalΒ financingΒ forΒ businessΒ growth.Β Additionally, the Company will continue to seek further opportunities for its water-based clean technology through active business development. The Directors remain confident in the Company's prospects for 2010 and beyond.

Enquiries:Β 

Ben Brewerton

Susan Quigley

Financial Dynamics

+44 (0) 20 7831 3113

Greg Bosch, CEO

Darren Weiss,Β CFO

PuriCore

+1 484 321 2700

About PuriCore

PuriCoreΒ plc (LSE: PURI) is aΒ water-based clean technologyΒ company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, wound care, and water treatment. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats ofΒ C.difficile,Β E.coli, HIV, Human and Animal Influenza (includingΒ H1N1 andΒ H5N1),Β Legionella, MRSA,Β M.tuberculosis, Norovirus, andΒ Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.Β 

To receive additional information on PuriCore, please visit our website atΒ www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All 2009Β financials are unaudited.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTEAAFNFELEEAF
Date   Source Headline
21st Nov 20177:00 amRNSRealm: Preclinical Data on PR022 Published
17th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20177:00 amRNSRealm Therapeutics to Present at BIO-Europe® 2017
30th Oct 20177:00 amRNSRealm Presents Data at ACAAI Scientific Meeting
18th Oct 20177:00 amRNSHolding(s) in Company
18th Oct 20177:00 amRNSBlock Listing Application
17th Oct 20176:28 pmRNSHolding(s) in Company
16th Oct 20173:39 pmRNSHolding(s) in Company
16th Oct 20177:00 amRNSRealm Therapeutics to speak at BIO Investor Forum
13th Oct 20172:20 pmRNSHolding(s) in Company
13th Oct 20172:17 pmRNSHolding(s) in Company
12th Oct 20175:48 pmRNSHolding(s) in Company
12th Oct 20173:07 pmRNSRealm Therapeutics: Completion of £19.3m Placing
12th Oct 201711:04 amRNSHolding(s) in Company
12th Oct 201710:58 amRNSHolding(s) in Company
9th Oct 201711:35 amRNSResult of General Meeting
22nd Sep 20177:00 amRNSProposed Placing to raise £19.3 million
22nd Sep 20177:00 amRNSInterim Results
21st Sep 20176:01 pmRNSProposed Placing to raise £19.3 million
21st Sep 20176:00 pmRNSInterim Results
11th Sep 20177:00 amRNSFDA Permits PR013 to Proceed to Phase II Trial
7th Sep 20177:00 amRNSConference Presentation
18th Aug 20177:00 amRNSBlock listing Interim Review
2nd Aug 20177:00 amRNSSubmission of Investigational New Drug Application
6th Jul 20177:00 amRNSPresentation at World Congress on Inflammation
14th Jun 20177:09 amRNSPresentation at 2017 Marcum Microcap Conference
6th Jun 201711:05 amRNSResult of AGM
11th May 201712:21 pmRNSNotice of AGM
23rd Mar 20172:57 pmRNSAnnual Report and Accounts Available
23rd Mar 20177:00 amRNSFinal Results and Business Update
6th Mar 20177:00 amRNSConference Presentation
28th Feb 20177:00 amRNSFDA permits PR022 to Proceed to Phase 2 Trial
20th Feb 20177:00 amRNSBlock listing Interim Review
13th Feb 20177:00 amRNSPresentation at BIO CEO & Investor Conference
30th Jan 20177:00 amRNSResearch Update - Submission of first IND
5th Jan 20177:00 amRNSConference Presentations
4th Jan 20177:00 amRNSGrant of Options
21st Dec 20167:00 amRNSPDMR dealing
16th Dec 20167:00 amRNSIvan Gergel appointed as Non-Executive Director
7th Dec 20167:00 amRNSChange of name to Realm Therapeutics
18th Nov 20167:00 amRNSGrant of Options
17th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 20167:00 amRNSDevelopment Programmes Update & Company Renaming
10th Oct 20167:00 amRNSCompletion of Supermarket Retail Business Disposal
7th Oct 20165:52 pmRNSCompletion of Supermarket Retail Business Disposal
6th Oct 201611:43 amRNSResult of General Meeting
23rd Sep 20162:47 pmRNSDirector/PDMR Dealing
22nd Sep 20162:15 pmRNSGrant of Options
20th Sep 20167:00 amRNSProposed Disposal of Supermarket Retail Business
20th Sep 20167:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.